THE first in a new class of
medicine that reduces the strain
on failing hearts and the risk
of cardiovascular death and
hospitalisation from systolic heart
failure compared to angiotensin
converting enzyme (ACE) inhibitor
therapy can now be prescribed in
Australia.
The new drug is Entresto
(sacubitril/valsartan) from Novartis,
an angiotensin receptor neprilsyn
inhibitor (ARNI), approved for
use in adults for the treatment of
chronic heart failure (NYHA Class IIIV)
with reduced ejection fraction.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Feb 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Feb 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.